合計 50 件の最近のインサイダー取引記録が記録されています Cullinan Therapeutics, Inc. (CGEM), 内訳は 22 件の買い および 25 件の売り. インサイダー買い総額は $36.66M インサイダー売り総額は $1.4M.
最近活動のある主要インサイダーには Michaelson Jennifer, Ahmed Nadim, Sumer Jacquelyn L. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — CGEM
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-05 |
Michaelson Jennifer |
Chief Scientific Officer |
オプション行使（売却） |
4,000 |
$4.30 |
$17.2K |
120,987 |
| 2026-02-25 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
1,780 |
$14.14 |
$25.17K |
174,844 |
| 2026-02-24 |
Ahmed Nadim |
President and CEO |
情報に基づく売り |
13,515 |
$14.47 |
$195.56K |
390,803 |
| 2026-02-24 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
3,601 |
$14.47 |
$52.11K |
176,624 |
| 2026-02-24 |
Sumer Jacquelyn L |
Chief Legal Officer |
情報に基づく売り |
3,601 |
$14.47 |
$52.11K |
128,089 |
| 2026-02-24 |
Jones Jeffrey Alan |
Chief Medical Officer |
情報に基づく売り |
4,582 |
$14.47 |
$66.3K |
159,968 |
| 2026-02-23 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
1,752 |
$13.99 |
$24.51K |
180,225 |
| 2026-02-20 |
Fenton Mary Kay |
Chief Financial Officer |
情報に基づく売り |
4,398 |
$13.62 |
$59.9K |
126,380 |
| 2026-02-20 |
Ahmed Nadim |
President and CEO |
情報に基づく売り |
16,381 |
$13.62 |
$223.11K |
404,318 |
| 2026-02-20 |
Michaelson Jennifer |
Chief Scientific Officer |
オプション行使（売却） |
8,000 |
$4.30 |
$34.4K |
124,987 |
| 2026-02-20 |
Sumer Jacquelyn L |
Chief Legal Officer |
情報に基づく売り |
3,742 |
$13.62 |
$50.97K |
131,690 |
| 2026-02-20 |
Jones Jeffrey Alan |
Chief Medical Officer |
情報に基づく売り |
4,982 |
$13.62 |
$67.85K |
164,550 |
| 2026-02-18 |
Fenton Mary Kay |
Chief Financial Officer |
RSU 付与（制限付株式） |
68,750 |
- |
- |
130,778 |
| 2026-02-18 |
Ahmed Nadim |
President and CEO |
RSU 付与（制限付株式） |
828,000 |
$12.44 |
$10.3M |
828,000 |
| 2026-02-18 |
Savill Corrine |
Chief Business Officer |
RSU 付与（制限付株式） |
175,000 |
$12.44 |
$2.18M |
175,000 |
| 2026-02-18 |
Michaelson Jennifer |
Chief Scientific Officer |
RSU 付与（制限付株式） |
115,000 |
$12.44 |
$1.43M |
115,000 |
| 2026-02-18 |
Sumer Jacquelyn L |
Chief Legal Officer |
RSU 付与（制限付株式） |
230,000 |
$12.44 |
$2.86M |
230,000 |
| 2026-02-18 |
Jones Jeffrey Alan |
Chief Medical Officer |
RSU 付与（制限付株式） |
300,000 |
$12.44 |
$3.73M |
300,000 |
| 2026-02-12 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
416 |
$12.03 |
$5K |
128,219 |
| 2026-01-22 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
4,000 |
$12.30 |
$49.2K |
128,635 |
| 2025-12-31 |
Fenton Mary Kay |
Chief Financial Officer |
RSU 付与（制限付株式） |
27 |
$6.49 |
$175.23 |
62,028 |
| 2025-12-23 |
Ahmed Nadim |
President and CEO |
情報に基づく売り |
9,922 |
$10.01 |
$99.32K |
420,699 |
| 2025-12-19 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
1,345 |
$10.01 |
$13.46K |
132,635 |
| 2025-12-18 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
2,898 |
$9.67 |
$28.02K |
133,980 |
| 2025-12-18 |
Sumer Jacquelyn L |
Chief Legal Officer |
情報に基づく売り |
3,480 |
$9.67 |
$33.65K |
135,432 |
| 2025-12-18 |
Jones Jeffrey Alan |
Chief Medical Officer |
情報に基づく売り |
4,632 |
$9.67 |
$44.79K |
169,532 |
| 2025-12-15 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
995 |
$11.90 |
$11.84K |
136,878 |
| 2025-12-12 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
2,148 |
$12.38 |
$26.59K |
137,873 |
| 2025-11-24 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
4,000 |
$12.30 |
$49.2K |
138,004 |
| 2025-10-28 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
165,667 |
$8.40 |
$1.39M |
8,963,500 |
| 2025-10-17 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
32,217 |
$7.84 |
$252.57K |
8,797,833 |
| 2025-10-16 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
150,000 |
$8.86 |
$1.33M |
8,765,616 |
| 2025-10-15 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
51,500 |
$7.94 |
$409.05K |
8,615,616 |
| 2025-10-14 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
15,032 |
$7.59 |
$114.05K |
8,564,116 |
| 2025-10-10 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
277,298 |
$7.36 |
$2.04M |
8,549,084 |
| 2025-10-09 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
626,043 |
$6.70 |
$4.19M |
8,271,786 |
| 2025-10-08 |
Lynx1 Capital Management Lp |
10 Percent Owner |
不明 |
- |
- |
- |
7,089,443 |
| 2025-10-08 |
Lynx1 Capital Management Lp |
10 Percent Owner |
情報に基づく買い |
556,300 |
$6.46 |
$3.59M |
7,645,743 |
| 2025-08-07 |
Allen Andrew R |
Officer |
不明 |
- |
- |
- |
- |
| 2025-08-07 |
Allen Andrew R |
Director |
RSU 付与（制限付株式） |
79,456 |
$7.03 |
$558.58K |
79,456 |
| 2025-08-07 |
Doyle Mittie |
Officer |
不明 |
- |
- |
- |
- |
| 2025-08-07 |
Doyle Mittie |
Director |
RSU 付与（制限付株式） |
79,456 |
$7.03 |
$558.58K |
79,456 |
| 2025-06-12 |
Webster Stephen W |
Director |
RSU 付与（制限付株式） |
38,513 |
$8.95 |
$344.69K |
38,513 |
| 2025-06-12 |
Rosenberg Anthony |
Director |
RSU 付与（制限付株式） |
38,513 |
$8.95 |
$344.69K |
38,513 |
| 2025-06-12 |
Meek David D. |
Director |
RSU 付与（制限付株式） |
38,513 |
$8.95 |
$344.69K |
38,513 |
| 2025-06-12 |
Martin Anne-marie |
Director |
RSU 付与（制限付株式） |
38,513 |
$8.95 |
$344.69K |
38,513 |
| 2025-06-12 |
Ryan David P. |
Director |
RSU 付与（制限付株式） |
38,513 |
$8.95 |
$344.69K |
38,513 |
| 2025-02-25 |
Ahmed Nadim |
President and CEO |
情報に基づく売り |
12,529 |
$8.53 |
$106.87K |
430,621 |
| 2025-02-25 |
Michaelson Jennifer |
Chief Scientific Officer |
情報に基づく売り |
3,756 |
$8.53 |
$32.04K |
142,004 |
| 2025-02-25 |
Sumer Jacquelyn L |
Chief Legal Officer |
情報に基づく売り |
3,756 |
$8.53 |
$32.04K |
136,895 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
